2024/08/08

Dong-A ST and its subsidiary NeuroBo Pharmaceuticals said they have entered into a joint research agreement with ImmunoForge to develop a long-acting obesity treatment using ImmunoForge’s one-month half-life ELP (Elastin-Like Polypeptide) platform technology.


Dong-A ST, NeuroBo Pharmaceuticals, and ImmunoForge plan to codevelop a long-acting obesity treatment.
Under the agreement, the companies will combine Dong-A ST and NeuroBo’s obesity treatment candidates with ImmunoForge’s ELP technology to develop a one-month long-acting obesity medication.

ImmunoForge’s ELP platform can extend the half-life of drugs by up to 200 times. ImmunoForge is now in phase 2 clinical trials for its ELP-based drug froniglutide as a treatment for polymyositis.

The company is also preparing to submit an IND for pemziviptadil, as a first-in-class drug for cardiomyopathy, to the U.S. Food and Drug Administration for phase 2 trials.

Several of ImmunoForge’s pipeline drugs have already received orphan drug designation from the FDA. In May last year, ImmunoForge successfully licensed its ELP technology-based drug to an unnamed global pharmaceutical company. The company seeks a Kosdaq listing by 2026.

“We have confirmed the potential to enhance and strengthen our obesity treatment pipeline through ImmunoForge’s ELP platform,” Dong-A ST President and CSO Park Jae-hong said. “We will closely collaborate with ImmunoForge to elevate our research and development capabilities and create best-in-class obesity treatments.”

ImmunoForge Co-CEOs Ahn Sung-min and Chang Ki-ho said, “We are pleased to reaffirm the potential and value of our ELP platform technology through this agreement with leading pharmaceutical companies Dong-A ST and NeuroBo.”

The co-CEOs added that their company would continue actively pursuing open innovation with Korean and international companies for its ELP platform.
 

Source : https://www.koreabiomed.com/news/articleView.html?idxno=24800